Insulin expressed from endogenously active glucose-responsive EGR1 promoter in bone marrow mesenchymal stromal cells as diabetes therapy

Gene Therapy

Volumn 17, Issue 5, 2010, Pages 592-605

  Chen, N K F ^a,b   Tan, S Y ^c   Udolph, G ^d   Kon, O L ^a,b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

Author keywords

Bone marrow mesenchymal stromal cells; Cell therapy; Diabetes mellitus; EGR1 promoter; Glucose responsive; Nonviral vector

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; EARLY GROWTH RESPONSE FACTOR 3; GENOMIC DNA; GLUCOSE; INSULIN; PLASMID DNA;

ANIMAL CELL; ARTICLE; AUTOTRANSPLANTATION; BODY WEIGHT; CELL COUNT; CELL THERAPY; CELL VIABILITY; CONTROLLED STUDY; DIABETES MELLITUS; DNA INTEGRATION; DRUG SAFETY; ELECTROPORATION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; IMMUNE RESPONSE; INSULIN RELEASE; MALE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RAT; TRANSGENE; XENOTRANSPLANTATION;

ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; DIABETES MELLITUS, EXPERIMENTAL; EARLY GROWTH RESPONSE PROTEIN 1; GENE THERAPY; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN; INSULIN-SECRETING CELLS; MALE; MESODERM; MICE; MICE, INBRED NOD; MICE, SCID; PROMOTER REGIONS, GENETIC; STROMAL CELLS; SWINE; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

MURINAE; MUS; SUS;

EID: 77952420524     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.12     Document Type: Article

References (50)

1. Shapiro AMJ, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318-1330.
2. Huurman VAL, Hilbrands R, Pinkse GGM, Gillard P, Duinker-ken G, van de Linde P et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 2008; 3: e2435.
3. Kobayashi N. The current status of islet transplantation and its perspectives. Rev Diabet Stud 2008; 5: 136-143.
4. Chen NKF, Sivalingam J, Tan SY, Kon OL. Plasmid-electro-porated primary hepatocytes acquire quasi-physiological secretion of human insulin and restore euglycemia in diabetic mice. Gene Ther 2005; 12: 655-667.
5. Chen NKF, Wong JS, Kee IHC, Lai SH, Thng CH, Ng WH et al. Nonvirally modified autologous primary hepatocytes correct diabetes and prevent target organ injury in a large preclinical model. PLoS One 2008; 3: e1734.
6. Keating A. Mesenchymal stromal cells. Curr Opin Hematol 2006; 13: 419-425.
7. Haleem-Smith H, Derfoul A, Okafor C, Tuli R, Olsen D, Hall DJ et al. Optimization of high-efficiency transfection of adult human mesenchymal stem cells in vitro. Mol Biotech 2005; 30: 9-19.
8. Wang Z, Troilo PJ, Wang X, Griffiths II TG, Pacchione SJ, Barnum AB et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electro-poration. Gene Ther 2004; 11: 711-721.
9. Josefsen K, Sørensen LR, Buschard K, Birkenbach M. Glucose induces early growth response gene (Egr-1) expression in pancreatic beta cells. Diabetologia 1999; 42: 195-203.
10. Hasan RN, Phukan S, Harada S. Differential regulation of early growth response gene-1 expression by insulin and glucose in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 988-993.
11. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsuli-naemia: the key feature of cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416-422.
12. Carrasco-Serrano C, Criado M. Glucocorticoid activation of the neuronal nicotinic acetylcholine receptor a7 subunit gene: involvement of transcription factor Egr-1. FEBS Lett 2004; 566: 247-250.
13. Barsoum J. Introduction of stable high-copy-number DNA into Chinese hamster ovary cells by electroporation. DNA Cell Biol 1990; 9: 293-300.
14. Kong Q, Wu M, Huan Y, Zhang L, Liu H, Bou G et al. Transgene expression is associated with copy number and cytomegalovirus promoter methylation in transgenic pigs. PLoS One 2009; 4: e6679.
15. Berry C, Hannenhalli S, Leipzig J, Bushman FD. Selection of target sites for mobile DNA integration in the human genome. PLoS Comput Biol 2006; 11: e157.
16. Fox A, Mountford J, Braakhuis A, Harrison LC. Innate and adaptive immune response to nonvascular xenografts: evidence that macrophages are direct effectors of xenograft rejection. J Immunol 2001; 166: 2133-2140.
17. Gabr MM, Sobh MM, Zakaria MM, Refaie AF, Ghoneim MA. Transplantation of insulin-producing clusters derived from adult bone marrow stem cells to treat diabetes in rats. Exp Clin Transplant 2008; 6: 236-243.
18. Kumar S, Chanda D, Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells. Gene Ther 2008; 15: 711-715.
19. Wang N, Fallavollita L, Nguyen L, Burnier J, Rafei M, Galipeau J et al. Autologous bone marrow stromal cells genetically engineered to secrete an IGF-I receptor decoy prevent the growth of liver metastases. Mol Ther 2009; 17: 1241-1249.
20. Campeau PM, Rafei M, François M, Birman E, Forner K-A, Galipeau J. Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Mol Ther 2009; 17: 369-372.
21. Xu R, Li H, Tse L-Y, Kung H-F, Lu H, Lam KS. Diabetes gene therapy: potential and challenges. Curr Gene Ther 2003; 3: 65-82.
22. Gill DR, Pringle IA, Hyde SC. Progress and Prospects: the design and production of plasmid vectors. Gene Ther 2009; 16: 165-171.
23. Kachi S, Esumi N, Zack DJ, Campochiaro PA. Sustained expression after nonviral ocular gene transfer using mammalian promoters. Gene Ther 2006; 13: 798-804.
24. Gros L, Montoliu L, Riu E, Lebrigard L, Bosch F. Regulated production of mature insulin by non-b-cells. Hum Gene Ther 1997; 8: 2249-2259.
25. Leibiger B, Moede T, Schwarz T, Brown GR, Köhler M, Leibiger IB et al. Short-term regulation of insulin gene transcription by glucose. Proc Natl Acad Sci USA 1998; 95: 9307-9312.
26. Herdegen T, Leah JD. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res Rev 1998; 28: 370-490.
27. Schwachtgen J-L, Campbell CJ, Braddock M. Full promoter sequence of human early growth response factor-1 (Egr-1): demonstration of a fifth functional serum response element. DNA Seq 2000; 10: 429-432.
28. Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 2002; 193: 287-292.
29. Berasi SP, Huard C, Li D, Shih HH, Sun Y, Zhong W et al. Inhibition of gluconeogenesis through transcriptional activation of EGR1 and DUSP4 by AMP-activated kinase. J Biol Chem 2006; 37: 27167-27177.
30. Eto K, Kaur V, Thomas M. Regulation of pancreas duodenum homeobox-1 expression by early growth response-1. J Biol Chem 2007; 282: 5973-5983.
31. Rhodes CJ. Processing of the insulin molecule. In: LeRoith D, Taylor SI, Olefsky JM (eds). Diabetes Mellitus: A Fundamental and Clinical Text, 3rd edn. Lippincott Williams & Wilkins: Philadelphia, USA, 2004, pp 27-50.
32. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001; 44: 929-945.
33. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1998; 318: 1231-1239.
34. Blackman JD, Polonsky KS, Jaspan JB, Sturis J, Cauter EV, Thistlethwaite JR et al. Insulin secretory profiles and C-peptide clearance kinetics at 6 months and 2 years after kidney-pancreas transplantation. Diabetes 1992; 41: 1346-1354.
35. Luzi L, Hering BJ, Socci C, Raptis G, Battezzati A, Terruzzi I et al. Metabolic effects of successful intraportal islet transplantation in insulin-dependent diabetes mellitus. J Clin Invest 1996; 97: 2611-2618.
36. Alejandro R, Barton FB, Hering BJ, Wease S. 2008 update from the collaborative islet transplant registry. Transplantation 2008; 86: 1783-1788.
37. Roach P, Woodworth JR. Clinical pharmacokinetics and phar-macodynamics of insulin lispro mixtures. Clin Pharmacokinet 2002; 41: 1043-1057.
38. Jones TW, Davis EA. Hypoglycemia in children with type 1 diabetes: current issues and controversies. Pediatr Diabetes 2003; 4: 143-150.
39. Xia Z, Taylor PR, Locklin RM, Gordon S, Cui Z, Triffitt JT. Innate immune response to human bone marrow fibroblastic cell implantation in CB17 Scid/Beige mice. J Cell Biochem 2006; 98: 966-980.
40. Fox A, Mountford J, Braakhuis A, Harrison LC. Innate and adaptive immune response to nonvascular xenografts: evidence that macrophages are direct effectors of xenograft rejection. J Immunol 2001; 166: 2133-2140.
41. Nasef A, Ashammakhi N, Fouillard L. Immunomodulatory effect of mesenchymal stromal cells: possible mechanisms. Regen Med 2008; 3: 531-546.
42. Prigozhina TB, Khitrin S, Elkin G, Eizik O, Morecki S, Slavin S. Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation. Exp Hematol 2008; 36: 1370-1376.
43. Medvinsky A, Smith A. Fusion brings down barriers. Science 2003; 422: 823-825.
44. Karp JM, Teo GSL. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009; 4: 206-216.
45. Lufino MMP, Edser PAH, Wade-Martins R. Advances in high-capacity extrachromosomal vector technology: episomal maintenance, vector delivery, and transgene expression. Mol Ther 2008; 16: 1525-1538.
46. Li S-D, Huang L. Non-viral is superior to viral gene delivery. J Control Release 2007; 123: 181-183.
47. Manzini S, Vargiolu A, Stehle IM, Bacci ML, Cerrito MG, Giovannoni R et al. Genetically modified pigs produced with a nonviral episomal vector. Proc Natl Acad Sci USA 2006; 103: 17672-17677.
48. Seaquist ER, Robertson RP. Effects of hemipancreatectomy on pancreatic alpha and beta cell function in healthy human donors. J Clin Invest 1992; 89: 1761-1766.
49. Bosch P, Pratt SL, Stice SL. Isolation, characterization, gene modification, and nuclear reprogramming of porcine mesench-ymal stem cells. Biol Reprod 2006; 74: 46-57.
50. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R. e potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.